Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204

Personal Subscription
Become EABM
Become Reviewer

Nerve Growth Factor Receptors and Signaling in Breast Cancer

Volume:4   Issue: 6
Pp: 463-470
Laurent Dolle, Eric Adriaenssens, Ikram El Yazidi-Belkoura, Xuefen Le Bourhis, Victor Nurcombe and Hubert Hondermarck
DOI: 10.2174/1568009043332853

Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?

Volume:4   Issue: 6
Pp: 471-482
E. Papadimitriou, A. Polykratis, M. Hatziapostolou, A. Parthymou, C. Polytarchou and C. Mikelis
DOI: 10.2174/1568009043332835

Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases

Volume:4   Issue: 6
Pp: 483-499
Thresia Thomas, Michael A. Gallo and T. J. Thomas
DOI: 10.2174/1568009043332880

Two-Domain Vascular Disruptive Agents in Cancer Therapy

Volume:4   Issue: 6
Pp: 501-509
Stanislaw Szala
DOI: 10.2174/1568009043332826

The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma

Volume:4   Issue: 6
Pp: 511-520
Noriyuki Takai, Tami Ueda, Masakazu Nishida, Kaei Nasu and Isao Miyakawa
DOI: 10.2174/1568009043332871

Mammaglobin-Based Strategies for Treatment of Breast Cancer

Volume:4   Issue: 6
Pp: 531-542
Peter S. Goedegebuure, Mark A. Watson, Carsten T. Viehl and Timothy P. Fleming
DOI: 10.2174/1568009043332862